Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOG2X1)

• Drug Name: Trebananib Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]
Renal cell carcinoma	2C90	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMOG2X1

Molecule-Related Drug Atlas

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[6]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[7]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[8]
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[9]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[10]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[12]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
REGN-910	DMHR7D4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]

Drug(s) Targeting Angiopoietin-1 (ANGPT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[6]
AMG 780	DMTGZN8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-1 (ANGPT1)	TTWNQ1T	ANGP1_HUMAN	Inhibitor	[4]
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [4] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [5] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Company report (Roche pipeline: July 27, 2017)
• [8] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of CovX (2011).
• [12] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [13] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [14] Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
• [15] Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.